Syndax Pharmaceuticals Inc (SNDX) concluded trading on Thursday at a closing price of $15.82, with 4.37 million shares of worth about $69.11 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -20.50% during that period and on February 06, 2025 the price saw a gain of about 7.99%. Currently the company’s common shares owned by public are about 85.57M shares, out of which, 81.08M shares are available for trading.
Stock saw a price change of 11.33% in past 5 days and over the past one month there was a price change of 15.56%. Year-to-date (YTD), SNDX shares are showing a performance of 19.67% which decreased to -25.69% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $12.06 but also hit the highest price of $25.34 during that period. The average intraday trading volume for Syndax Pharmaceuticals Inc shares is 2.51 million. The stock is currently trading 13.81% above its 20-day simple moving average (SMA20), while that difference is up 10.31% for SMA50 and it goes to -15.33% lower than SMA200.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) currently have 85.57M outstanding shares and institutions hold larger chunk of about 109.07% of that.
The stock has a current market capitalization of $1.35B and its 3Y-monthly beta is at 0.94. It has posted earnings per share of -$3.63 in the same period. It has Quick Ratio of 6.99 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SNDX, volatility over the week remained 4.64% while standing at 4.92% over the month.
Stock’s fiscal year EPS is expected to drop by -17.06% while it is estimated to decrease by -12.47% in next year. EPS is likely to grow at an annualized rate of 3.72% for next 5-years, compared to annual growth of -0.41% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on October 24, 2024 offering a Buy rating for the stock and assigned a target price of $37 to it. Coverage by Jefferies stated Syndax Pharmaceuticals Inc (SNDX) stock as a Buy in their note to investors on June 28, 2024, suggesting a price target of $37 for the stock. On January 31, 2024, Scotiabank Downgrade their recommendations, while on December 22, 2023, Mizuho Initiated their ratings for the stock with a price target of $45. Stock get a Buy rating from BofA Securities on October 25, 2023.
